National Resilience Inc., a new company backed by a rich $800m investment and an impressive leadership pedigree, aims to tackle next-generation biopharma manufacturing challenges, starting in 2021. The company will focus on developing new technologies to manufacture the most complex medicines including cell and gene therapies, viral vectors, vaccines and proteins.
"We are working on technology that is disruptive. It's not just process-development of existing platforms," CEO Rahul Singhvi said in...








